GET DAILY SIGNALSWhy Is Alnylam Pharmaceuticals (ALNY) Stock Down -16.27% Today?
Key Takeaways
- Shares fell 16.27%, or about $37.82, to $194.58 from a prior close of $232.40.
- Primary catalyst: Third-quarter 2026 results and a full-year 2026 revenue outlook that landed below Wall Street consensus.
- Secondary drivers: A headline earnings "beat" driven largely by a one-time tax benefit, slowing TTR-franchise growth, and margin pressure from royalty payments.
- Broader context: The move diverged from a comparatively resilient biotech tape, signaling company-specific concerns rather than a sector-wide sell-off.
- What to watch next: Upcoming HELIOS-B data, the cemdisiran regulatory decision, and management's commentary on AMVUTTRA demand trends.
- For additional details on Price Targets, Earnings, and Forecast, explore the dedicated pages for this ticker.
- Discover which AI trading strategies are performing best right now by exploring Trending AI Robots.
Opening Summary
Alnylam Pharmaceuticals, Inc. (ALNY), the Cambridge, Massachusetts-based pioneer of RNA interference (RNAi) therapeutics best known for its ATTR amyloidosis franchise led by AMVUTTRA, saw its stock plunge 16.27% in Thursday's session. The shares traded at $194.58, down $37.82 from the previous close of $232.40, as investors digested the company's third-quarter 2026 earnings report. While reported revenue and earnings per share exceeded analyst estimates, the market focused instead on a full-year revenue guidance range that fell short of consensus expectations and raised fresh questions about the durability of growth in the company's core TTR product line.
Third-Quarter Results and the Guidance Gap
The sharp decline was primarily an earnings-driven move. Alnylam reported third-quarter revenue of roughly $1.46 billion, up 17% year over year and modestly ahead of the approximately $1.43 billion consensus. Total net product revenue climbed 52% to $1.29 billion, led by AMVUTTRA, which grew 65% to about $1.13 billion. However, the apparent earnings beat was heavily distorted by a roughly $1.9 billion non-cash income-tax benefit tied to the release of valuation allowances on deferred tax assets, rather than core operational strength.
More consequential for sentiment was the company's full-year 2026 revenue outlook. Alnylam reiterated total net product revenue guidance of approximately $4.7 billion to $5.1 billion, a range that sits well below the analyst consensus near $5.48 billion. The gap reinforced concerns that initial patient demand for AMVUTTRA is normalizing, tempering the growth trajectory that had underpinned the stock's valuation. Investors interpreted the reiterated guidance as a signal that the TTR franchise's rapid expansion is decelerating.
Margin Pressure and Cost Concerns
Compounding the guidance disappointment were signs of eroding profitability at the product level. Cost of goods sold as a percentage of net product revenues rose to 28.0% from 23.2% a year earlier, driven by higher blended royalty rates payable to Sanofi on AMVUTTRA sales. GAAP and non-GAAP operating income both declined year over year, underscoring that the headline net-income surge was not reflective of underlying operating leverage. Rising research and development spending tied to late-stage programs such as ZENITH and TRITON-CM further pressured near-term profitability.
Regulatory Overhang
The move also unfolded against the backdrop of a previously announced securities-fraud investigation tied to an earlier reduction in 2026 sales guidance of roughly $200 million. While not a new catalyst on the day, the investigation continues to weigh on investor confidence and has heightened sensitivity to any messaging around forward sales expectations. The combination of a below-consensus outlook and lingering disclosure-related scrutiny left little room for the stock to hold its recent levels.
Market Context and Trading Activity
Trading in ALNY was heavy and conviction-driven, reflecting a clear re-rating rather than a passive drift. The decline stood in contrast to a relatively steadier broader biotechnology complex, indicating that the price action was primarily company-specific. The stock's move through prior support levels erased much of the stabilization seen earlier in the week and placed the shares near multi-month lows, as institutional repositioning followed the guidance shortfall.
What Comes Next for ALNY
Attention now turns to a series of near-term catalysts that could either stabilize or further pressure the shares. Alnylam is set to present two-year open-label extension results from the HELIOS-B Phase 3 trial of vutrisiran at the American Heart Association Scientific Sessions in early November, and an indirect treatment comparison at the International Symposium of Amyloidosis later that month. A PDUFA target action date for cemdisiran in generalized myasthenia gravis is also expected in November, with Regeneron advancing the candidate. Additionally, the company signaled it will report Phase 2 data for ALN-6400 and Phase 1 data for ALN-2232 alongside its fourth-quarter results in February 2027.
Risks remain tilted toward execution and demand visibility. Should AMVUTTRA growth continue to decelerate, or should late-stage RNAi programs disappoint, the valuation could face further pressure. Conversely, positive clinical readouts and a successful cemdisiran approval could restore confidence in the pipeline's long-term diversification. Investors will be watching management's commentary closely for any signal on whether the current guidance range proves conservative or reflects a more durable slowdown.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that are currently delivering the strongest performance under prevailing market conditions. While Tickeron offers hundreds of bots covering thousands of tickers, only the top performers are featured in this section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade. Explore the Trending AI Robots to see which automated strategies are gaining momentum today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
ALNY in downward trend: price dove below 50-day moving average on October 01, 2026
ALNY moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend. In 31 of 38 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 82%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for ALNY crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
The Aroon Indicator for ALNY entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALNY's RSI Oscillator exited the oversold zone, 16 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 64 cases where ALNY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on ALNY as a result. In 61 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for ALNY just turned positive on October 16, 2026. Looking at past instances where ALNY's MACD turned positive, the stock continued to rise in 33 of 46 cases over the following month. The odds of a continued upward trend are 72%.
Following a +4.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALNY advanced for three days, in 219 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
ALNY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. ALNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.965) is normal, around the industry mean (3.151). P/E Ratio (39.591) is within average values for comparable stocks, (-1.051). Projected Growth (PEG Ratio) (0.330) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (127.720) among similar stocks. P/S Ratio (6.911) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutics based on RNA interference
Industry Biotechnology
Advertisement